International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Amgen Announced the United States Food and Drug Administration (FDA) Approval of AMJEVITA™

Psoriasis News Amgen Blog Graphic

Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.



Recent Posts

Expert Insights IPC and IFPA CEO

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

New Councilor Headshots

Meet Our Newest Councilors

IPC and IFPA strongly advocate that early diagnosis is crucial and must be available for all individuals regardless of race, ethnicity, physical ability, culture, nationality, or geographic location blog graphic

IPC and IFPA Joint Statement on Diversity and Inclusion

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.